Previous Close | 3.7500 |
Open | 3.8000 |
Bid | 3.5000 |
Ask | 3.6000 |
Strike | 17.50 |
Expire Date | 2025-01-17 |
Day's Range | 3.5000 - 4.3000 |
Contract Range | N/A |
Volume | |
Open Interest | 2.61k |
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. Novavax, which struggled to get its protein-based vaccine to the market in a timely manner, also removed a warning notice from February last year that raised doubts about it being in business after the deal. The fund, which owns an about 7.8% stake in Novavax, reiterated that the Sanofi agreement was a "long-awaited step in the right direction".